In Silico identification and modelling of FDA-approved drugs targeting T-type calcium channels
Pedro Fong, Susana Román García, Melanie I. Stefan, David C. Sterratt
This paper identifies montelukast, an FDA-approved asthma drug, as a potential inhibitor of the Cav3.1 T-type calcium channel through computational simulations and suggests it may have therapeutic potential for neurological diseases.
bioRxiv · Sep 27, 2024 · PreprintBioinformatics